|
WO2010148288A2
|
|
Pharmaceutical formulations with low aqueous levels of free unbound drug
|
|
JP2009242423A
|
|
Coated particle, its production method and using method
|
|
CA2710418A1
|
|
Stabilized formulations of peptides and proteins
|
|
CA2672024A1
|
|
Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
|
|
US2008145434A1
|
|
Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
|
|
AU2006236616A1
|
|
Formulations of quaternary ammonium neuromuscular blocking agents
|
|
US2006141544A1
|
|
Compositions for binding to assay substrata and methods of using
|
|
WO2006041878A2
|
|
Primary examiner
|
|
US7713440B2
|
|
Stabilized uncoated particles of reversed liquid crystalline phase materials
|
|
US7758890B2
|
|
Treatment using dantrolene
|
|
AU2004262507A1
|
|
Treatment using dantrolene
|
|
AU2003258075A1
|
|
Lipid-drug complexes in reversed liquid and liquid crystalline phases
|
|
WO03106382A2
|
|
Reversed liquid crystalline phases with non-paraffin hydrophobes
|
|
US6991809B2
|
|
Particles with improved solubilization capacity
|
|
CA2488643A1
|
|
Coated particles, methods of making and using
|
|
WO03106589A1
|
|
A nanoporous particle with a retained target
|
|
AU2002312476A1
|
|
Coated particles, methods of making and using
|
|
WO03000057A1
|
|
Solvent system
|
|
WO03106168A1
|
|
Coated particles, methods of making and using
|
|
US6638621B2
|
|
Coated particles, methods of making and using
|
